FDA Mandates Vision Loss Warning on All GLP-1 Drug Labels
The U.S. Food and Drug Administration will require a warning about potential permanent vision loss linked to a rare eye condition on the labels of all GLP-1 medications, including Ozempic, Wegovy, Zepbound, and Mounjaro.
The U.S. Food and Drug Administration (FDA) announced on Monday that it will require a warning about possible permanent vision loss on the labels of all GLP-1 drugs. The labeling requirement applies to widely used medications including Ozempic, Wegovy, Zepbound, and Mounjaro.
The warning addresses non-arteritic anterior ischemic optic neuropathy (NAION), a painless eye condition caused by decreased blood flow to the optic nerve. Symptoms of NAION include blurred vision, blind spots, distorted colors, and other visual irregularities. An analysis of more than 125 clinical trials found that NAION occurred in roughly six of every 100,000 patients who took a GLP-1 medication for at least one year.
Health Canada announced last month that it had identified a potential safety risk related to Ozempic, Rybelsus, and Wegovy concerning NAION, though those findings have not yet been published.
Beyond vision risks, recent research has examined other health outcomes associated with GLP-1 usage. Research presented at the American Society of Clinical Oncology in June found that patients taking GLP-1 drugs showed lower risks of developing cancer and disease progression compared to those not taking them. The study also noted improved survival and responses to some treatments.
Conversely, a British Medical Association study involving just over 50,000 people—with between 11,000 and 15,000 people in each drug-class group—found that GLP-1 usage was associated with a 37 per cent higher risk of alopecia compared with SGLT-2 inhibitors and a 68 per cent higher risk than DPP-4 inhibitors. Dr. Elena Netchiporouk noted that hair loss might be a result of rapid weight loss rather than the drug itself.